^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WTX-124

    i
    Associations
    News

    Trials

    Company:
    Werewolf Therap
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors (KEYNOTE-D17) (NCT05479812)
    Phase 1
    Werewolf Therapeutics, Inc.
    Recruiting
    Last update posted :
    12/27/2024
    Initiation :
    05/20/2022
    Primary completion :
    07/01/2025
    Completion :
    07/31/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • WTX-124